TG-4050 is under clinical development by Transgene and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TG-4050 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TG-4050 overview

TG-4050 is under development for the treatment of ovarian, fallopian and peritoneal serous carcinoma, head and neck cancer and head and neck cancer squamous cell carcinoma. It is administered through subcutaneous route. The drug candidate is developed based on myvac platform, modified vaccinia virus ankara (MVA) viral vector based personalized immunotherapy.

Transgene overview

Transgene, a subsidiary of Institut Merieux SA, operates as a biotechnology company that includes discovery and development of immunotherapies in the areas of cancer and infectious diseases. It provides products such as TG4050, TG4001, TG600, BT-001 and TG6050. The company’s products therapeutic areas include colorectal cancer (IV), colorectal cancers (IAH), HPV-positive cancers and non-small cell lung cancer. Transgene carries out technology platforms such as myvac and invir.IO. It operates through collaborations with numerous reference clinical centers, university hospitals and medical centers. It has operations in France, the US and China. Transgene is headquartered in Illkirch-Graffenstaden, Alsace, France.

For a complete picture of TG-4050’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.